In a report released today, Peter Welford from Jefferies maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price target of £20.00. The company’s shares closed ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50. The company’s shares closed yesterday at p1,497. ...

TOWN OF DICKINSON, N.Y. (WIVT/WBGH) – Broome County Sheriff’s Office Corrections Officers and Deputies will be adorned with a ...

Designer Jill Martin was diagnosed with Stage 2 breast cancer in 2023. The NBA and WNBA logos are turning pink for Breast Cancer Awareness Month. Designer and breast cancer survivor Jill Martin ...

Teva Pharmaceutical Industries Ltd. ADR-0.76% $19.75B ...

Sept 11 (Reuters) - British drugmaker GSK (GSK.L), opens new tab said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main goal of a mid-stage trial ...

iTeos Therapeutics (NASDAQ:ITOS) announced Saturday that its experimental cancer doublet therapy developed with GSK (NYSE:GSK) outperformed the British drugmaker’s FDA-approved anti-PD-1 therapy ...

GSK has turned to Brooke Shields to get the message out about shingles vaccination. The drugmaker has worked with the model and actor to talk to female celebrities and patients aged 50 years and ...

GSK has demonstrated robust sales growth, with a 13% increase to GBP 7.9 billion and a core operating profit up by 21% to GBP 2.5 billion, as noted by CEO Emma Walmsley in the latest earnings call.

As part of the agreement, GSK, Sanofi, and CSL will produce extra bulk vaccine components tailored to the circulating strains of avian influenza. Also Read: Medicare Drug Price Negotiation Program ...

This summer, GSK cut its yearly vaccine sales projection on the back of a narrowed recommendation for adult respiratory syncytial virus (RSV) vaccines from the Centers for Disease Control and ...

GSK’s (NYSE:GSK) investigational herpes simplex virus (HSV) vaccine candidate failed to meet the primary goal of a mid-stage trial and will not progress to a late-stage trial. The British ...